Clinical Trials Browser

Not yet recruiting × Ovarian Neoplasms × famitinib × Clear all

NCT07382713 2026-02-03

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms